{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-217302","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2024-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.900948+00:00","generated_at":"2026-05-31T05:27:08.394689+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ovid Therapeutics appoints Meg Alexander as President and COO effective Sept 9","bullets":["Annual base salary of $500,000; target bonus of 45% of base salary.","Granted option to purchase 140,000 shares at $1.07 per share, 10-year term.","Option vests 25% on one-year anniversary, then monthly over 36 months.","Severance includes 12 months salary and COBRA gross-up on covered termination.","Alexander previously served as Chief Strategy Officer since June 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-217302","json":"https://secwatch.observer/filing/0001193125-24-217302.json","markdown":"https://secwatch.observer/filing/0001193125-24-217302.md","text":"https://secwatch.observer/filing/0001193125-24-217302.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000119312524217302/0001193125-24-217302-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000119312524217302/d869021d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:27:08.394689+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"912d34cfc5","claim":"Margaret \"Meg\" Alexander was appointed as President and Chief Operating Officer at Ovid Therapeutics Inc..","evidence_excerpt":"On September 8, 2024, the Board of Directors of Ovid Therapeutics Inc. (the “Company”) appointed Margaret “Meg” Alexander, the Company’s Chief Strategy Officer, to President and Chief Operating Officer (“COO”) of the Company, effective September 9, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000119312524217302/0001193125-24-217302-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}